Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings
Kinnate Biopharma, focused on small molecule kinase inhibitors, announced presentations at two key scientific meetings. The AACR Special Conference: Targeting RAS will feature a study on the prevalence of Class II and III BRAF mutation-positive solid tumors. The presentation is scheduled for January 8, 2022. Additionally, the ASCO GI Cancers Symposium, on January 21, 2022, will showcase results from preclinical studies evaluating KIN-3248, a promising FGFR inhibitor. The company aims to improve targeted therapies for genomically defined cancers.
- None.
- None.
AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF mutation-positive (BRAF+) solid tumors
ASCO GI Cancers Symposium presentation will highlight results from preclinical studies evaluating the company’s lead Fibroblast Growth Factor Receptor (FGFR) inhibitor candidate, KIN-3248
SAN FRANCISCO and SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the company will present at two upcoming scientific meetings, the AACR Special Conference: Targeting RAS, being held January 7-10, 2022 in Lake Buena Vista, Florida and the ASCO GI Cancers Symposium, being held January 20-22 in San Francisco, California.
“Since our founding, Kinnate has been driven by our mission to expand the availability of targeted therapies to all patients who may benefit from them,” said Richard Williams, MBBS, Ph.D., Chief Medical Officer at Kinnate. “We are very pleased with the continued progress of both our RAF and FGFR inhibitor programs and look forward to sharing these updates with the oncology community at these upcoming meetings.”
Details of the upcoming AACR Special Conference: Targeting RAS presentation, which will be delivered by Paul Severson, Ph.D., Kinnate’s Senior Director of Translational Medicine and Bioinformatics, are as follows:
- Abstract title: Real-World Clinico-Genomic Analysis of Patients with BRAF Mutated Solid Tumors Identifies BRAF Class II and III as a Significant Population of Unmet Need
- Session: Poster Session A
- Session date and time: Saturday, January 8, 2022, from 4:45PM -7:00PM ET
Additional information on the AACR Special Conference: Targeting RAS is available through the conference website at: https://www.aacr.org/meeting/targeting-ras-2022.
Details of the upcoming ASCO GI Cancers Symposium presentation, which will be delivered by Aleksandra Franovic, Ph.D., Senior Director of Translational Medicine at Kinnate, are as follows:
- Abstract title: Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations
- Session: Poster Session B
- Session date and time: Friday, January 21, 2022, from 3:05PM – 4:35PM ET
Additional information on the ASCO GI Cancers Symposium is available through the conference website at: https://conferences.asco.org/gi.
About Kinnate
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products that are designed to address significant unmet need. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors. For more information, please visit www.kinnate.com.
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements include, without limitation, statements regarding our expected presentations at scientific conferences, the progress of our research and development programs (including our ongoing clinical trial) and the potential benefits of our product candidates. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are also intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends. Such expectations and projections may never materialize or may prove to be incorrect. These forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors, including risks related to operating as a preclinical-stage biopharmaceutical company with a limited operating history; our ability to raise additional capital to finance our operations; our ability to discover, advance through the preclinical and clinical development of, obtain regulatory approval for and commercialize our product candidates; the novel approach we are taking to discover and develop drugs; our ability to timely file and obtain approval of investigational new drug applications for our planned clinical trials; the potential for any clinical trial results to differ from our preclinical study results; negative impacts of the COVID-19 pandemic on our business, including ongoing and planned clinical trials and ongoing and planned preclinical studies; competition in our industry; regulatory developments in the United States and other countries; our ability to attract, hire and retain highly skilled executive officers and employees; difficulties in managing our growth; our ability to protect our intellectual property; reliance on third parties to conduct our preclinical studies and any ongoing or planned future clinical trials, and to manufacture our product candidates; general economic and market conditions; and other risks.
These and other risks, uncertainties, assumptions and other factors are further described under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 that we have filed with the Securities and Exchange Commission (the “SEC”), as well as in our subsequent filings we make with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. Investors should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Our forward-looking statements speak only as of the date of this release, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason in the future.
Contacts:
Investors:
Patti Bank
Westwicke, an ICR Company
415-513-1284
investors@kinnate.com
Media:
Colin Sanford
203-918-4347
colin@bioscribe.com
FAQ
What will Kinnate Biopharma present at the AACR Special Conference on January 8, 2022?
When is Kinnate Biopharma presenting at the ASCO GI Cancers Symposium?
What is KIN-3248 in relation to Kinnate Biopharma's research?
How does Kinnate Biopharma aim to address unmet needs in oncology?
What is the focus of Kinnate Biopharma's research presented at the conferences?
